



Authors:

Mona O. Mohsen, Daniel E. Speiser, Justine Michaux, HuiSong Pak, Brian J. Stevenson, Monique Vogel, Varghese P. Inchakalody, Simone de Brot, George Coukos, Said Dermime, Michal Bassani-Sternberg and Martin F. Bachmann

Correspondence:

mona.mohsen@dbmr.unibe.ch
 michal.bassani@chuv.ch

In Brief

We have identified neoantigenic peptides by integrating peptidomics, genetics and transcriptomic techniques. A personalized multi-target VLP-based vaccine was developed by coupling the neoantigenic peptides using Cu-free click chemistry. The developed vaccine showed promising anti-tumour response that can readily be implemented for clinical use.